1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty therapeutics companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous niche market sub-segments and business models where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important businesses. The firm targets $10-$30 million investments in commercial healthcare entities that we believe have the potential to scale to approximately $100 million of revenue, a level we believe is highly attractive for acquisition or to access the public markets.
In addition to experienced investing partners, 1315 Capital leverages an operating partner model of CEO and “Right Hand” COO Executive, a partnership that works together to navigate diligence, drive decisions, and seeks to achieve premium exits. Three operating teams contribute their collective experience to 1315 Capital in the areas of medical technologies, healthcare services, and specialty therapeutics. These three teams have built companies from expansion and growth phases to entities with revenues in excess of $100 million, resulting in almost $5 billion of aggregate exit value.
In addition to experienced investing partners, 1315 Capital leverages an operating partner model of CEO and “Right Hand” COO Executive, a partnership that works together to navigate diligence, drive decisions, and seeks to achieve premium exits. Three operating teams contribute their collective experience to 1315 Capital in the areas of medical technologies, healthcare services, and specialty therapeutics. These three teams have built companies from expansion and growth phases to entities with revenues in excess of $100 million, resulting in almost $5 billion of aggregate exit value.
Location: United States, Pennsylvania, Philadelphia
Employees: 11-50
Founded date: 2014
Investment Type: Venture Capital
Investment Stage: Seed
Portfolio 26
Date | Name | Website | Total Raised | Location |
08.08.2024 | NuTek BioS... | nu-tekbiosciences.com | - | - |
08.08.2024 | Medivant H... | medivanthealth.com | - | - |
08.08.2024 | Primrose B... | primrosebio.com | - | United Sta... |
08.08.2024 | Spineology... | spineology.com | $45M | United Sta... |
07.02.2024 | Triple Rin... | tripleringtech.com | - | United Sta... |
07.07.2023 | CortiCare | corticare.com | - | United Sta... |
04.10.2022 | Innovative... | innovativeecmo.com | - | United Sta... |
22.07.2022 | 3B Scienti... | 3bscientific.com | - | Germany, H... |
14.07.2022 | NutriSense | nutrisense.io | $25M | United Sta... |
13.01.2020 | Interpace ... | interpace.com | $20M | United Sta... |
Show more
Persons 7
Date | First Name | Last Name | Title | Location | |||
- | Katherine | Medlock | Associate | - | - | - | |
- | Tristan | Rekdahl | Senior Acc... | - | - | - | |
- | Matthew | Reber | Partner | - | - | - | |
- | Craig | Matturro | Principal | - | - | - | |
- | Michael | Koby | Founding P... | - | - | - | |
- | Ian | B. Li | Principal | - | - | - | |
- | Rob | Schrepfer | Operating ... | - | - | - |
News 208
Show more
Mentions in press and media 29
Date | Title | Description |
30.10.2024 | Experic Receives Growth Investment | Experic, a Cranbury, NJ-based contract development and manufacturing organization (CDMO) and clinical trial supply services company, received a growth investment of an undisclosed amount. Backers included 1315 Capital, East Seattle Partners... |
12.08.2024 | Spineology: Medical Device Company Raises $25 Million (Series AA) | Spineology, a medical device company pioneering Conform and Expand spinal fusion technology, announced that it has raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing i... |
06.08.2024 | Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated Op... | ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology, the medical device company pioneering Conform and Expand™ spinal fusion technology, today announced that it has raised $25 million in Series AA financing led by SV Health Investors, with partici... |
25.10.2023 | 1315 Capital closes two funds and bags over $500m | |
23.10.2023 | 1315 Capital Closes Two Funds, Raising over $500 Million to Invest in Commercial-Stage Hea... | - |
13.01.2020 | Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital a... | - |
13.02.2018 | Term Sheet — Tuesday, February 13 | BIOTECH BOOM Good morning, Term Sheet readers. Paid Content A.I. is the answer to protecting your enterprise in the cloud From ExtraHop We think poor people should benefit from the same kind of innovation in health and agriculture that has ... |
12.02.2018 | 1315 Capital Completes Single Close on Over $300M Healthcare Growth Equity Fund | 1315 Capital, LLC, an expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology and healthcare services companies, today announced the single close of 1315 Capital II, a healthcare growth... |
12.02.2018 | 1315 Capital Closes Healthcare Growth Equity Fund, at Over $300M | 1315 Capital, LLC, a Philadelphia, PA-based expansion and growth equity firm that invests in commercial-stage specialty pharmaceutical, medical technology and healthcare services companies, closed a growth fund, at over $300m. Similar to th... |
12.02.2018 | 1315 Capital Completes Single Close on Over $300 Million Healthcare Growth Equity Fund | - |
Show more